01:33 PM EDT, 03/10/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) is planning to enroll ~180 HR+/HER2- mBC patients in a large Phase 2 clinical trial that the company anticipates will support an accelerated approval of pelareorep in breast cancer.

Management anticipates that it can generate the primary endpoint (PFS) within two years following the start of patient enrollment, which is expected in the second half of 2025, notes RBC.

The company presented two posters focusing on research in anal and pancreatic cancers at the ASCO Gastrointestinal Cancers Symposium held in San Francisco in January, highlighting pelareorep's potential across multiple indications.

RBC has trimmed its one year target by $1, to $5 as it incorporates equity financing and corresponding dilution. Maintain Outperform/Speculative Risk.

Price: 0.95, Change: -0.05, Percent Change: -4.55